
Share
A year after outbidding Novo Nordisk for Metsera, Pfizer turns to Blackstone Life Sciences for non-dilutive capital, structuring a milestone-based deal that keeps full control of its cardiometabolic crown jewel.
Pfizer has secured up to $1.5 billion from Blackstone Life Sciences to fund clinical testing of berobenatide, the long-acting GLP-1 peptide at the center of its cardiometabolic strategy. The agreement, announced after market close on Wednesday, structures the capital as milestone-based financing rather than equity or debt. Blackstone takes on development risk in exchange for payments tied to regulatory and commercial progress. Pfizer keeps the asset entirely.
That distinction matters. Pfizer's Chief Financial Officer and Executive Vice President Cecile Guegan framed the deal as part of a broader capital strategy: pairing internal R&D spending with targeted outside investment. "Today's announcement helps us advance our comprehensive obesity program and maintain the financial capacity and flexibility to invest in our broader pipeline across all therapeutic areas," she said. Translation: Pfizer wants to fund a sprawling obesity program without diverting cash from the rest of its portfolio.
Berobenatide arrived at Pfizer through an expensive and competitive process. The peptide, formerly known as MET-097i, was the lead obesity candidate at Metsera. Novo Nordisk wanted it badly, seeing it as a potential successor to its weekly injectable Wegovy. Pfizer's own oral GLP-1 program, danuglipron, had stumbled over liver enzyme concerns, pushing the company to look outward for its next metabolic bet. About a year ago, Pfizer won the bidding war with a $10 billion offer for Metsera, beating Novo outright.
Monthly dosing is the core commercial pitch. Wegovy and Lilly's Zepbound both require weekly injections. If berobenatide can match their efficacy with a quarter of the dosing frequency, Pfizer has a genuine differentiation argument in a crowded field. The company says its clinical program could eventually grow to more than 20 trials, covering obesity and related comorbidities including knee osteoarthritis and obstructive sleep apnea. Pfizer is also testing berobenatide as a monotherapy and in combination with other nutrient-stimulated hormone peptides, including amylin analogs that affect blood sugar and appetite regulation.
Pfizer is not entering a quiet market. Novo and Lilly already dominate GLP-1 peptide therapeutics, and both have been expanding their labels well beyond weight loss. Wegovy has picked up FDA approval to treat MASH, the fatty liver disease, and its oral version carries an indication for reducing major cardiovascular events. Lilly's Zepbound added obstructive sleep apnea to its label in late 2024.
Lilly is also pushing efficacy rather than convenience with retatrutide, a triple agonist hitting GLP-1, GIP, and glucagon receptors. That drug is in a broad trial program spanning obesity, type 2 diabetes, and related metabolic disorders. Where Pfizer is betting on dosing frequency as the differentiator, Lilly is betting on raw therapeutic power. Investors should watch how these two strategies play out in head-to-head efficacy and adherence data, because the market will likely reward whichever argument proves more durable with physicians and payers.

Pfizer's cardiometabolic pipeline now spans more than one asset. Last December, the company acquired an oral GLP-1 drug from Shanghai-based YaoPharma, giving it a second mechanism to pursue alongside berobenatide. That diversification suggests Pfizer is hedging against the possibility that monthly dosing alone won't be enough to compete with Novo and Lilly's established franchises.
The Blackstone relationship is not new territory for either side. Blackstone Life Sciences has built a pattern of funding late-stage biopharma programs in exchange for milestone or royalty rights. Earlier this year, the firm committed up to $1.3 billion to Apogee Therapeutics to support late-stage development of a long-acting antibody for atopic dermatitis, structured around royalties on an approved product. Apogee was then acquired by AbbVie for roughly $11 billion, a quick and lucrative exit for Blackstone's capital. The firm has also struck similar arrangements with Moderna around its influenza program and with Alnylam Pharmaceuticals, both involving milestone payments and royalty streams.
Under the Pfizer agreement, funds managed by Blackstone's perpetual private equity strategy will invest alongside Blackstone Life Sciences funds. Milestone payments, if triggered, will be disbursed over a multi-year period. Blackstone gains no rights to berobenatide itself. Pfizer retains full control over the clinical program and all downstream commercial decisions.
The financial terms of the milestone structure were not disclosed, but given the scale of the global cardiometabolic market, those payments could be substantial if berobenatide clears regulatory hurdles. For Pfizer, the deal is a way to fund an ambitious, 20-plus trial obesity program without straining its balance sheet or diluting shareholders. For Blackstone, it's another bet in a growing book of biopharma financing deals that have, in at least one case, paid off handsomely through a strategic acquisition.
The risk sits with execution. Berobenatide still needs to prove its efficacy and safety across a wide range of indications, competing against two entrenched leaders with approved, revenue-generating products. Monthly dosing is an attractive selling point, but it won't matter if the drug underperforms on weight loss or cardiovascular outcomes relative to Wegovy or Zepbound. Pfizer paid $10 billion to acquire this asset and is now layering on up to $1.5 billion in non-dilutive financing. The combined bet is large, and the market will be watching trial readouts closely to see whether the convenience argument holds up against Lilly's efficacy-first approach with retatrutide.
Tags
Original Sources
Pfizer Deal With Blackstone Secures Up to $1.5B to Bankroll GLP-1 Drug Trials - MedCity News
↗ https://medcitynews.com/2026/11/pfizer-blackstone-life-sciences-long-acting-glp-1-berobenatide-metabolic-obesity-weight-management-pfe
About the author
Marcus began tracking AI's market implications in 2016, noticing AI-related patent filings accelerating ahead of earnings upgrades before most of the sell-side had caught on. A former fixed-income quantitative analyst, he spent two decades building models that priced risk across emerging markets before pivoting to cover the economic impact of AI full-time. His writing translates opaque technical developments into clear risk/reward terms — and he's rarely diplomatic about the gap between AI valuations and underlying fundamentals. He believes most market participants still underestimate AI's long-run deflationary effect on knowledge work.
More from The Analyst →This Week's Edition
13 November 2026
14 articles
Related Articles
Related Articles
More Stories
© 2026 Cedar & Bloom. All rights reserved.